Hangang Sacred Heart Hospital   Report issue

Academic/Hospital Phase 3
Founded: Seoul Korea, Republic of (1971)

Organization Overview

First Clinical Trial
2007
NCT00978705
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hangang Sacred Heart Hospital | the Translational Research Program for Rehabilitation Robots (NRCTR-EX19002)

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous cultured keratinocyte (1 trial)

Drugs in Other Trials (2)

vasopressin (vasostrict) (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3